Urogen Pharma (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 60,677 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the completion of the sale, the insider directly owned 59,086 shares in the company, valued at approximately $2,779,996.30. This trade represents a 50.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Mark Schoenberg also recently made the following trade(s):
- On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00.
- On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00.
- On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total value of $142,560.60.
Urogen Pharma Trading Down 1.5%
Shares of NASDAQ URGN traded down $0.70 during mid-day trading on Monday, hitting $46.16. The company had a trading volume of 849,674 shares, compared to its average volume of 817,922. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $50.81. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -23.31 and a beta of 1.57. The stock’s 50-day moving average price is $40.51 and its 200-day moving average price is $29.14.
Hedge Funds Weigh In On Urogen Pharma
A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its position in shares of Urogen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after buying an additional 88,577 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares in the last quarter. Jane Street Group LLC increased its stake in Urogen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after acquiring an additional 24,839 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Urogen Pharma during the second quarter valued at about $361,000. Finally, JPMorgan Chase & Co. lifted its stake in Urogen Pharma by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock worth $5,348,000 after purchasing an additional 19,405 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on URGN. Oppenheimer upped their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price target for the company. Guggenheim upped their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. HC Wainwright lifted their price objective on Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, TD Cowen boosted their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.38.
Check Out Our Latest Research Report on Urogen Pharma
About Urogen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
See Also
- Five stocks we like better than Urogen Pharma
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
